Core needle biopsy (CNB) is currently considered the method of choice for tissue sampling to evaluate histopathological and biological features of breast lesions (1). The immunohistochemical (IHC) characterization of biomarkers status preceding surgical treatment is crucial when primary systemic therapy (neoadjuvant) or intraoperatory radiotherapy (IORT) are a therapeutic option. Surrogate definition of genetically- and molecularly-defined intrinsic breast cancer (BC) sub-types are typically based on the IHC staining for estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth receptor factor 2 (HER2). The classification group tumours includes Luminal, HER2- enriched and Triple Negative (2). The IHC assessment of Ki-67 antigen is used to evaluate the proliferative activity of BC. Ki-67 “high” expression is related to high risk of relapse and worse survival, but there is no standardized Ki-67 pathological interpretation and Ki-67 high expression cut-off value. The aim of the study is to assess the concordance between CNB and paired surgical resection specimen (SS) in evaluating biomarkers and molecular subtypes of early BC.

Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes

Pedriali, M
Primo
;
Galli, G;Artusi, E;Schirone, A;Querzoli, P
Ultimo
2017

Abstract

Core needle biopsy (CNB) is currently considered the method of choice for tissue sampling to evaluate histopathological and biological features of breast lesions (1). The immunohistochemical (IHC) characterization of biomarkers status preceding surgical treatment is crucial when primary systemic therapy (neoadjuvant) or intraoperatory radiotherapy (IORT) are a therapeutic option. Surrogate definition of genetically- and molecularly-defined intrinsic breast cancer (BC) sub-types are typically based on the IHC staining for estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth receptor factor 2 (HER2). The classification group tumours includes Luminal, HER2- enriched and Triple Negative (2). The IHC assessment of Ki-67 antigen is used to evaluate the proliferative activity of BC. Ki-67 “high” expression is related to high risk of relapse and worse survival, but there is no standardized Ki-67 pathological interpretation and Ki-67 high expression cut-off value. The aim of the study is to assess the concordance between CNB and paired surgical resection specimen (SS) in evaluating biomarkers and molecular subtypes of early BC.
Breast Cancer
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2383567
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact